PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange reports that laboratory trials have proven that the excipients included in the placebo used in its trial in combination with the drug MTX improves the drug’s performance in treating rheumatoid arthritis. Can-Fite lately reported the results of a Phase IIb clinical trial that had evaluated the safety and efficacy of a combination of CF101 and MTX in treating rheumatoid arthritis patients. A high number of patients (50%) responded with a 20% improvement in the disease indices (ACR20), both in the control group and in groups that had been treated with CF101 in combination with MTX. This percentage of responders in the control group is an unprecedented phenomenon, and is higher than that which has thus far been described in the literature. As a result, Can-Fite conducted the trials with the drug excipient and, indeed, found that it had acted as an anti-inflammatory substance and significantly enhanced the MTX drug efficacy.
